| Literature DB >> 32551354 |
Maryam Kasraeian1, Kamran Hessami1,2, Homeira Vafaei1, Nasrin Asadi1, Leila Foroughinia3, Shohreh Roozmeh1, Khadije Bazrfashan1.
Abstract
Cervical cancer is among the most common causes of cancer-related deaths in low- and middle-income countries (LMICs). Despite the strong evidence regarding cervical cancer screening cost-effectiveness, its utilization remains low especially in high risk populations such as HIV-positive women. The aim of this review was to provide an overview on the patient-reported factors influencing cervical cancer screening uptake among HIV-positive women living in LMICs. We systematically searched EMBASE, PUBMED/MEDLINE and Web of Science databases to identify all quantitative and qualitative studies investigating the patient-reported barriers or facilitators to cervical cancer screening uptake among HIV-positive population from LMICs. A total of 32 studies met the inclusion criteria. A large number of barriers/facilitators were identified and then grouped into three categories of personal, social and structural variables. However, the most common influential factors include knowledge and attitude toward cervical cancer or its screening, embarrassment, fear of cervical cancer screening and test results, patient-healthcare provider relationship, social support, screening costs and time constraints. This review's findings highlighted the need for multi-level participation of policy makers, health professionals, patients and their families in order to overcome the barriers to uptake of cervical cancer screening among HIV-positive women, who are of special concern in LMICs.Entities:
Keywords: Barriers; Cervical cancer; Facilitators; Low‐ and middle‐income countries; Patient-reported; Screening
Year: 2020 PMID: 32551354 PMCID: PMC7292910 DOI: 10.1016/j.gore.2020.100596
Source DB: PubMed Journal: Gynecol Oncol Rep ISSN: 2352-5789
Fig. 1Literature search and review flowchart for selection of studies.
Quantitative and mixed-method studies conducted in Western Africa.
| First author, year | Country | Study design | Study setting | Population | Age | Screening status | Type of screening | Patient-reported factors influencing women’s cervical cancer screening experience. The (+/−) signs indicate women’s perception of how these factors influenced their screening experience. | MMAT score |
|---|---|---|---|---|---|---|---|---|---|
| Nigeria | Cross-sectional study | Voluntary Counseling and Testing (VCT) clinic of the University of Nigeria Teaching Hospital in Enugu, Nigeria | 150 HIV-positive women and 150 HIV-negative women | 21–54 years, mean age 34.9 year | 0.7% screened at least once | Pap test | 50% | ||
| Nigeria | Descriptive cross-sectional study | ART clinic at the Nnamdi Azikiwe University Teaching Hospital, tertiary health care in Nnewi, south-eastern Nigeria | 447 HIV-positive women | NR | 10% screened at least once | Pap test | 75% | ||
| Nigeria | Cross-sectional study | HIV treatment center, Nigerian Institute of Medical Research | 1517 HIV-positive women | 18–57 years, mean age 31 year | 9.4% screened at least once | NR | 75% | ||
| Nigeria | Descriptive cross-sectional study | ART clinic of the Lagos State University Teaching Hospital, Ikeja, Lagos State, Nigeria | 300 HIV-positive women | 17–60 years, mean age 34 year | 31.3% screened at least once | Pap test | 50% | ||
| Ivory Coast (Côte d’Ivoire) | Cross-sectional study | Outpatient setting in the four highest volume urban HIV clinics of government’s or non-governmental organisation’s sector in Côte d’Ivoire | 1991 HIV-positive women | Inter Quartile Range of 37–47 years, median age 42 | 59.7% screened at least once | Pap test and VIA | 75% | ||
| Ghana | Descriptive cross-sectional study | HIV health facilities in the Central Region of Ghana | 660 HIV-positive women | 20–65 years | NR | NR | 100% | ||
| Ghana | Mixed methods | Cape Coast Teaching | 55 HIV-positive women and 76 HIV-negative women | Mean age 42.9 year | NR | NR | 50% |
ART anti-retroviral therapy, HCP healthcare provider, HIV human immunodeficiency virus, MMAT mixed methods appraisal tool, NR not reported, OR odds ratio, VIA visual inspection with acetic acid.
Quantitative and mixed-method studies conducted in Southern Africa.
| First author, year | Country | Study design | Study setting | Population | Age | Screening status | Type of screening | Patient-reported factors influencing women’s cervical cancer screening experience. The (+/−) signs indicate women’s perception of how these factors influenced their screening experience. | MMAT score |
|---|---|---|---|---|---|---|---|---|---|
| South Africa | Cross-sectional study | Secondary referral obstetrics and gynecology hospital, Lower Umfolozi District War Memorial Hospital, in rural KwaZulu-Natal | 79 HIV-positive women and 155 HIV-negative women | 18–70 years, mean age 29 year | 32.5% screened at least once | Pap test | 75% | ||
| South Africa | Mixed-methods* | Rural HIV clinic in Limpopo Province, South Africa | 403 HIV-positive women for quantitative and 12 HIV-positive women for qualitative study | NR | NR | VIA and Pap test | 25% | ||
| South Africa | Descriptive cross-sectional study | Adult HIV unit at a publichospital in Johannesburg, South Africa | 315 HIV-positive women | 27–54 years, mean age 38.9 year | NR | Pap test | 50% | ||
| South Africa | Cross-sectional study | ART clinic at GF Jooste Hospital, Cape Town, South Africa | 100 HIV-positive women | 21–64 years, mean age 32.8 year | 59% screened at least once | Pap test | 50% | ||
| Botswana | Cross-sectional study | Two public health clinics in Gaborone, Botswana | 163 HIV-positive women and 117 HIV-negative women | 20–84 years | 72% screened at least once | Pap test | 50% |
ART anti-retroviral therapy, HCP healthcare provider, HIV human immunodeficiency virus, MMAT mixed methods appraisal tool, NR not reported, OR odds ratio, VIA visual inspection with acetic acid
*Quantitative data of this mix-methods study is not presented since it was not patient-reported factors and it only reported patients’ medical records data.
Quantitative and mixed-method studies conducted in Eastern Africa.
| First author, year | Country | Study design | Study setting | Population | Age | Screening status | Type of screening | Patient-reported factors influencing women’s cervical cancer screening experience. The (+/−) signs indicate women’s perception of how these factors influenced their screening experience. | MMAT score |
|---|---|---|---|---|---|---|---|---|---|
| Ethiopia | Cross-sectional study | Three public health facilities providing both cervical cancer screening and assisted reproductive technology services in Hawassa, Ethiopia | 342 HIV-positive women | Mean age 33.4 year | 40.1% screened within previous five years | NR | 75% | ||
| Ethiopia | Mixed methods | Public health institutions of HIV care in Addis Ababa, Ethiopia | 322 HIV-positive women for quantitative and 14 HIV-positive women for qualitative study | Mean age 35.7 years | 11.5% screened at least once | NR | 75% | ||
| Ethiopia | Cross-sectional study | ART clinic at University of Gondar | 302 HIV-positive women | Mean age 33.7 year | 23.5% screened at least once | NR | 75% | ||
| Ethiopia | Mixed methods | Public (community) health centers in Addis Ababa, the capital city of Ethiopia | 581 HIV-positive women | 21–64 years, mean age 34.9 year | 10.8% screened at least once | NR | 75% | ||
| Ethiopia | Cross-sectional study | Hospital based setting In Bishoftu town, East Shoa, Ethiopia | 475 HIV-positive women | 18–67 years, mean age 36.2 year | 24.8% screened at least once | VIA | 100% | ||
| Kenya | Mixed methods | Kenyatta National Hospital, Nairobi, Kenya | 387 HIV-positive women for quantitative study and 4 focus group discussions (each group = 6–8 HIV-positive women) | Inter Quartile Range of 36–44 years, median age 40 | 46.3% screened at least once | NR | 50% | ||
| Kenya | Descriptive cross-sectional study | Voluntary counseling and testing centers in Nairobi, Kenya | 268 HIV-positive women and 141 HIV-negative women | Inter Quartile Range of 24–34 years, median age 28 | 14% screened at least once | Pap test | 75% | ||
| Kenya | Cross-sectional study | Integrated HIV clinic in the Nyanza Province of Kenya | 106 HIV-positive women | 23–64 years, mean age 34.9 year | 15% screened at least once | NR | 75% | ||
| Zimbabwe | Descriptive cross-sectional study | Bindura Provincial Hospital, Zimbabwe | 70 HIV-positive women | 19–49 years, mean age 35.7 year | NR | NR | 25% | ||
| Tanzania | Cross-sectional study | HIV clinics in Dar es Salaam, Tanzania | 399 HIV-positive women | ≥19 years | 9% screened at least once | NR | 100% | ||
| Uganda | Nationwide cross-sectional study | 245 public and private HIV clinics across the five geographical regions (Central, Northern, Eastern, Western, and Kampala) in Uganda | 5198 HIV-positive women | 15–49 years | 30.3% screened at least once | NR | 100% |
ART anti-retroviral therapy, HCP healthcare provider, HIV human immunodeficiency virus, MMAT mixed methods appraisal tool, NR not reported, PR prevalence ratio, OR odds ratio, VIA visual inspection with acetic acid.
Quantitative and mixed-method studies conducted in other countries.
| First author, year | Country | Study design | Study setting | Population | Age | Screening status | Type of screening | Patient-reported factors influencing women’s cervical cancer screening experience. The (+/−) signs indicate women’s perception of how these factors influenced their screening experience. | MMAT score |
|---|---|---|---|---|---|---|---|---|---|
| Morocco | Cross-sectional study | HIV treatment center at the Hospital of Moulay Hassan Ben Elmehdi in Laâyoune city, Morocco | 115 HIV-positive women | Mean age 34.9 years | 13% screened at least once | Pap test | 50% | ||
| Peru | Cross-sectional study | Vía Libre non-governmental organization (NGO) HIV center in Lima, Peru | 71 HIV-positive women | 19–60 years, mean age 40.4 year | 12.7% never had a Pap test, 77.5% had over 1 year ago, 9.8% within 1 year | Pap test | 50% | ||
| Laos | Cross-sectional case–control study | HIV treatment centers of three provinces of Lao PDR, Vientiane, Luang Prabang and Savannakhet | 320 HIV-positive women (cases) and 320 HIV-negative women (controls) | 25–63 years, mean age 36.2 year | 5.6% screened at least once | Pap test | 100% |
HCP healthcare provider, HIV human immunodeficiency virus, MMAT mixed methods appraisal tool.
Qualitative studies included.
| First author, year | Country | Study design | Studysetting | Population | Age | Screening status | Type of screening | Patient-reported factors influencing women’s cervical cancer screening experience. The (+/−) signs indicate women’s perception of how these factors influenced their screening experience. | MMAT score |
|---|---|---|---|---|---|---|---|---|---|
| Tanzania | Focus group discussions | Twelve Management and Development for Health (MDH) public HIV centers in Dar es Salaam, Tanzania | 19 HIV-positive women | 24–57 years | NR | NR | 75% | ||
| Uganda | In-depth interview | HIV specialist care organization of Mildmay Uganda | 18 HIV-positive women | ≥25 years | 1/3 not screened, 1/3 screened once, 1/3 screened on a regular basis | VILI, VIA | 100% | ||
| India | Semi-structured in-depth interviews | New Civil Hospital ART Centrein Surat, India | 25 HIV-positive women | 30–54 years, mean age 37.2 year | 88% screened at least once | Pap test | 75% | ||
| Botswana | Semi-structured interviews | Oodi rural clinic in the Kgatleng district of Botswana | 14 HIV-positive women | 29–49 years, mean age 37.4 year | 71.4% screened at least once | Pap test and VIA | 50% | ||
| Zambia | In-depth interviews | Urban and rural health care facilities in Lusaka and Chongwe districts, Zambia | 19 HIV-positive women, 19 HIV-negative women and 2 women with unknown HIV status | 25–49 years | 52.5% screened at least once | NR | 50% | ||
| Zambia | Focus group discussions and in-depth interviews | Zambian Ministry of Health primary health center in Kanyama | 20 HIV positive women and 40 HIV-negative women | 18–49 years | NR | VIA | 75% |
ART anti-retroviral therapy, HCP healthcare provider, HIV human immunodeficiency virus, MMAT mixed methods appraisal tool, NR not reported, VIA visual inspection with acetic acid, VILI visual inspection with Lugol’s iodine.